Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis

BACKGROUND: Research on JAK family members as therapeutic targets for autoimmune diseases has brought tofacitinib and baricitinib into clinical for the treatment of rheumatoid arthritis and other autoimmune diseases. Despite the potent efficacy of these first-generation JAK inhibitors, their broad-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ning, Zhang, Changqing, Zeng, Zhihong, Zhang, Jiyong, Du, Shengnan, Bao, Chunde, Wang, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153205/
https://www.ncbi.nlm.nih.gov/pubmed/34054304
http://dx.doi.org/10.2147/JIR.S301076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153205/
https://www.ncbi.nlm.nih.gov/pubmed/34054304
http://dx.doi.org/10.2147/JIR.S301076

Ejemplares similares